RGNX

+ Watchlist + Portfolio

REGENXBIO Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Fundamentals are temporarily unavailable for RGNX.

RGNX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$112.72M	$90.24M	$83.33M	$170.44M
Cost of Revenue	$54.55M	$37.21M	$33.57M	$20.30M
Gross Profit	$58.18M	$53.03M	$49.76M	$150.14M
Research & Development	$242.45M	$232.27M	$208.52M	$228.30M
Selling, General & Admin	$85.28M	$88.49M	$76.62M	$82.86M
Operating Expenses	$321.06M	$321.16M	$281.01M	$311.34M
Operating Income	-$262.88M	-$268.13M	-$231.25M	-$161.20M
EBITDA	-$244.24M	-$239.46M	-$198.23M	-$133.25M
Pretax Income	-$280.40M	-$263.65M	-$227.10M	-$193.88M
Income Tax	-$84.00K	-$152.00K	$0.00	—
Net Income	-$280.32M	-$263.49M	-$227.10M	-$193.88M
Diluted EPS	-6.50	-6.02	-4.59	-3.76
Diluted Shares	43.15M	43.73M	49.51M	51.57M

RGNX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$96.95M	$34.52M	$57.53M	$34.47M
Receivables	$30.29M	$26.34M	$21.57M	$27.38M
Current Assets	$415.98M	$334.97M	$278.00M	$281.28M
Total Assets	$833.27M	$573.97M	$465.99M	$453.03M
Current Liabilities	$130.43M	$130.27M	$103.19M	$118.09M
Total Debt	$94.80M	$89.29M	$82.03M	$73.50M
Total Liabilities	$317.07M	$262.23M	$206.34M	$350.30M
Retained Earnings	-$441.55M	-$705.05M	-$932.15M	-$1.13B
Shareholders' Equity	$516.20M	$311.74M	$259.65M	$102.73M
Working Capital	$285.54M	$204.70M	$174.81M	$163.19M

RGNX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$207.49M	-$218.41M	-$173.13M	-$123.96M
Capital Expenditure	-$30.72M	-$9.96M	-$2.44M	-$2.41M
Free Cash Flow	-$238.21M	-$228.37M	-$175.56M	-$126.38M
Depreciation & Amortisation	$12.91M	$17.32M	$16.21M	$15.62M
Stock-Based Compensation	$40.79M	$40.27M	$38.46M	$34.56M
Investing Cash Flow	-$11.93M	$190.94M	$103.45M	-$15.87M
Financing Cash Flow	-$28.84M	-$34.97M	$92.68M	$116.77M
Net Change in Cash	-$248.26M	-$62.43M	$23.00M	-$23.06M

RGNX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$89.01M	$21.36M	$29.73M	$30.34M	$6.39M	$108.02M
Cost of Revenue	$3.44M	$5.21M	$5.72M	$5.93M	$11.07M	$1.04M
Gross Profit	$85.58M	$16.15M	$24.01M	$24.41M	-$4.68M	$106.98M
Research & Development	$53.09M	$59.50M	$56.10M	$59.61M	$57.34M	$56.09M
Selling, General & Admin	$20.35M	$19.88M	$20.25M	$22.38M	$21.31M	$21.62M
Operating Expenses	$73.45M	$79.43M	$76.42M	$82.05M	$78.68M	$77.71M
Operating Income	$12.13M	-$63.28M	-$52.41M	-$57.64M	-$83.36M	$29.26M
EBITDA	$18.61M	-$55.97M	-$44.89M	-$51.00M	-$77.49M	$34.26M
Pretax Income	$6.08M	-$70.87M	-$61.94M	-$67.15M	-$90.05M	$22.71M
Net Income	$6.08M	-$70.87M	-$61.94M	-$67.15M	-$90.05M	$22.71M
Diluted EPS	0.12	-1.38	-1.20	-1.30	-1.72	0.43
Diluted Shares	51.43M	51.48M	51.69M	51.75M	52.43M	53.02M

RGNX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$130.10M	$79.56M	$58.80M	$34.47M	$15.23M	$36.49M
Receivables	$19.16M	$21.49M	$26.47M	$27.38M	$10.94M	$107.10M
Current Assets	$313.24M	$373.75M	$331.97M	$281.28M	$186.52M	$236.16M
Total Assets	$490.93M	$581.03M	$525.20M	$453.03M	$341.89M	$386.62M
Current Liabilities	$106.73M	$119.54M	$124.57M	$118.09M	$71.11M	$82.62M
Total Debt	$79.85M	$77.70M	$76.51M	$73.50M	$71.07M	$68.95M
Total Liabilities	$216.73M	$367.35M	$363.75M	$350.30M	$320.81M	$314.85M
Retained Earnings	-$926.07M	-$996.94M	-$1.06B	-$1.13B	-$1.22B	-$1.19B
Shareholders' Equity	$274.20M	$213.68M	$161.45M	$102.73M	$21.08M	$71.77M
Working Capital	$206.51M	$254.21M	$207.40M	$163.19M	$115.41M	$153.54M

RGNX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$33.63M	-$49.34M	-$55.96M	-$52.29M	-$76.19M	-$62.24M
Capital Expenditure	-$1.02M	-$391.00K	-$491.00K	-$508.00K	-$1.24M	-$760.00K
Free Cash Flow	$32.60M	-$49.73M	-$56.45M	-$52.80M	-$77.42M	-$63.00M
Depreciation & Amortisation	$3.96M	$3.90M	$3.89M	$3.87M	$3.86M	$3.76M
Stock-Based Compensation	$8.54M	$8.65M	$9.00M	$8.38M	$8.62M	$9.05M
Investing Cash Flow	$44.74M	-$140.44M	$42.29M	$37.54M	$70.59M	$65.92M
Financing Cash Flow	-$5.79M	$139.23M	-$7.08M	-$9.58M	-$13.64M	$17.57M
Net Change in Cash	$72.58M	-$50.55M	-$20.76M	-$24.34M	-$19.24M	$21.26M

Market Snapshot

About

REGENXBIO is a clinical-stage biotechnology company developing gene therapies using its proprietary adeno-associated virus (AAV) platform. The company advances treatments for genetic diseases affecting the eye, liver, and central nervous system. REGENXBIO also licenses its NAV Technology Platform to other biotech and pharmaceutical companies, creating a dual revenue model from internal development and technology partnerships.